We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Catalyst Pharmaceutical (CPRX) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
Catalyst Pharmaceutical (CPRX - Free Report) closed the most recent trading day at $20.27, moving -0.78% from the previous trading session. This change lagged the S&P 500's daily loss of 0.76%. At the same time, the Dow lost 0.76%, and the tech-heavy Nasdaq lost 10.92%.
Heading into today, shares of the specialty drug company had gained 4.77% over the past month, outpacing the Medical sector's loss of 0.24% and the S&P 500's gain of 2.18% in that time.
Investors will be hoping for strength from Catalyst Pharmaceutical as it approaches its next earnings release. The company is expected to report EPS of $0.20, up 122.22% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $56.61 million, up 47.77% from the prior-year quarter.
Any recent changes to analyst estimates for Catalyst Pharmaceutical should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 6.35% higher. Catalyst Pharmaceutical is holding a Zacks Rank of #4 (Sell) right now.
Valuation is also important, so investors should note that Catalyst Pharmaceutical has a Forward P/E ratio of 22.87 right now. This represents a premium compared to its industry's average Forward P/E of 13.17.
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 89, which puts it in the top 36% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Catalyst Pharmaceutical (CPRX) Dips More Than Broader Markets: What You Should Know
Catalyst Pharmaceutical (CPRX - Free Report) closed the most recent trading day at $20.27, moving -0.78% from the previous trading session. This change lagged the S&P 500's daily loss of 0.76%. At the same time, the Dow lost 0.76%, and the tech-heavy Nasdaq lost 10.92%.
Heading into today, shares of the specialty drug company had gained 4.77% over the past month, outpacing the Medical sector's loss of 0.24% and the S&P 500's gain of 2.18% in that time.
Investors will be hoping for strength from Catalyst Pharmaceutical as it approaches its next earnings release. The company is expected to report EPS of $0.20, up 122.22% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $56.61 million, up 47.77% from the prior-year quarter.
Any recent changes to analyst estimates for Catalyst Pharmaceutical should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 6.35% higher. Catalyst Pharmaceutical is holding a Zacks Rank of #4 (Sell) right now.
Valuation is also important, so investors should note that Catalyst Pharmaceutical has a Forward P/E ratio of 22.87 right now. This represents a premium compared to its industry's average Forward P/E of 13.17.
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 89, which puts it in the top 36% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.